Across 76 weeks in obesity/overweight without type 2 diabetes, survodutide achieved up to 16.6% mean weight loss versus 3.2% ...

However, gastrointestinal adverse events -- primarily nausea, vomiting, diarrhea, and constipation -- occurred in 80.9-89.7% ...

GoodRx reports that GLP-1 medications, while not FDA-approved for high blood pressure, can aid in lowering it through weight ...

The GLP-1 agonists weight loss drugs market offers growth potential through rising obesity rates, innovative drug approvals, and increased insurance coverage. Opportunities include expanding obesity ...

The results of two phase 3 trials investigating Survodutide, a weight loss drug from Boehringer Ingelheim, suggest that the ...

Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.

Researchers from the University of Copenhagen are introducing a new biological concept in the fight against diabetes: glucagon resistance. Glucagon resistance or decreased sensitivity to the hormone ...

While wholesale costs for glucagon skyrocketed over the past decade, out-of-pocket costs haven't increased by much, researchers reported. The cost of unmixed glucagon increased 192% from 2010 to 2020 ...